Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nitro G is a sublingual spray formulation of nitroglycerin (glyceryl trinitrate), a potent vasodilator used for the acute relief and prophylaxis of angina pectoris. It is designed for rapid absorption through the oral mucosa, allowing the active ingredient to bypass first-pass hepatic metabolism and enter the systemic circulation quickly. Nitroglycerin acts as a prodrug that is bioactivated by mitochondrial aldehyde dehydrogenase (ALDH2) to release nitric oxide (NO). The released nitric oxide then stimulates soluble guanylate cyclase (sGC), increasing the intracellular concentration of cyclic guanosine monophosphate (cGMP). This increase in cGMP activates protein kinase G, leading to the dephosphorylation of myosin light chains and the relaxation of vascular smooth muscle. The resulting systemic vasodilation primarily affects the venous system, reducing venous return (preload) and myocardial wall tension, which decreases myocardial oxygen demand and alleviates anginal pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nitro G.